Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia

M Gbadamosi, S Meshinchi, JK Lamba - Future Oncology, 2018 - Taylor & Francis
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
被引用次数：29 相关文章

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

M Gbadamosi, S Meshinchi… - Future Oncology (London …, 2018 - europepmc.org
Abstract In September 2017, the US FDA announced re-approval of gemtuzumab
ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and …
[HTML] nih.gov

[HTML][HTML] Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia

M Gbadamosi, S Meshinchi, JK Lamba - Future Oncology, 2018 - ncbi.nlm.nih.gov
Abstract In September 2017, the US FDA announced re-approval of gemtuzumab
ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and …

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia

M Gbadamosi, S Meshinchi… - Future oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia

M Gbadamosi, S Meshinchi, JK Lamba - Future Oncology, 2018 - search.proquest.com
Abstract In September 2017, the US FDA announced re-approval of gemtuzumab
ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and …
[PDF] academia.edu

[PDF][PDF] Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia

M Gbadamosi, S Meshinchi, JK Lamba - 2018 - academia.edu
Background Acute myeloid leukemia (AML) is a heterogeneous disease affecting
hematopoietic stem and progenitor cells, and is characterized by impairment in the …

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

M Gbadamosi, S Meshinchi… - Future Oncology (London …, 2018 - europepmc.org
Abstract In September 2017, the US FDA announced re-approval of gemtuzumab
ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and …